Management of haemorrhagic complications associated with oral anticoagulant treatment

Expert Opinion on Drug Safety

Volumn 1, Issue 2, 2002, Pages 129-136

  Beyth, Rebecca J ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

anticoagulant therapy; bleeding; managementrisk factors

Indexed keywords

ANTICOAGULANT AGENT; VITAMIN K GROUP; WARFARIN;

AGED; BLEEDING; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXPERT WITNESS; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; EXPERT TESTIMONY; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VITAMIN K; WARFARIN;

EID: 0042736672     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.2.129     Document Type: Review

References (92)

1. SEVITT S, GALLAGHER NG: Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet (1959) 2:981-989.
2. POWERS PJ, GENT M, JAY RM et al.: A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch. Intern. Med. (1989) 149:771-774. (Pubitemid 19132995)
3. GENT M, ROBERTS RS: A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis. Chest (1986) 89(Suppl. 5):396S-400S. (Pubitemid 16035647)
4. TABERNER DA, POLLER L, BURSLEM RW, JONES JB: Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br. Med. J. (1978) 1:272-274. (Pubitemid 8316106)
5. POLLER L, MCKERNAN A, THOMSON JM, ELSTEIN M, HIRSCH PJ, JONES JB: Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br. Med. J. (1987) 295(6609):1309-1312. (Pubitemid 18003544)
6. NIH CONSENSUS CONFERENCE: Prevention of venous thrombosis and pulmonary embolism. JAMA (1986) 256:744-749.
7. HULL R, DELMORE T, GENTON E et al.: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thromboembolism. N. Engl. J. Med. (1979) 301(16):855-858. (Pubitemid 10165871)
8. LAGERSTEDT CI, FAGHER BO, ALBRECHTSSON U et al.: Need for longterm anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet (1985) 2:515-518. (Pubitemid 15236478)
9. HULL RD, RASKOB GE, ROSENBLOOM D et al.: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N. Engl. J. Med. (1990) 322:1260-1264. (Pubitemid 20152488)
10. GALLUS A, JACKAMAN J, TILLETT J, MILLS W, WYCHERLEY A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet (1986) 2(8519):1293-1296. (Pubitemid 17177862)
11. FRANCIS CW, MARDER VJ, EVARTS CM et al.: Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA (1983) 249:374-378. (Pubitemid 13167236)
12. RESNIKOV L, CHEDIAK J, HIRSH J, LEWIS HDJR: Antithrombotic agents in coronary artery disease. Chest (1989) 95(2 Suppl.):52S-72S. (Pubitemid 19045156)
13. GOLDBERG RJ, GORE JM, DALEN JE, ALPERT JS: Long-term anticoagulant therapy after acute myocardial infarction. Am. Heart J. (1985) 109(3 Pt 1):616-662.
14. MEDICAL RESEARCH COUNCIL GROUP: Assessment of short-term anticoagulant administration after cardiac infarction: report of the working party on anticoagulant therapy in coronary thrombosis. Br. Med. J. (1969) 1:335-342.
15. VETERANS ADMINISTRATION COOPERATIVE STUDY: Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. JAMA (1973) 225:724-729.
16. DRAPKIN A, MERSKEY C: Anticoagulant therapy after acute myocardial infarction. JAMA (1972) 222:541-548.
17. SIXTY-PLUS REINFARCTION STUDY GROUP: A double-blind trial to assess longterm oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet (1980) 2:989-994.
18. SMITH LA, BRANCH LG, SCHERR PA et al.: Short-term variability of measures of physical function in older people. J. Am. Geriatr. Soc. (1990) 38:993-998. (Pubitemid 20329562)
19. MOK CK, BOEY J, WANG R et al.: Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective clinical trial. Circulation (1985) 72(5):1059-1063. (Pubitemid 16205407)
20. TURPIE AGG, GUNSTENSEN J, HIRSH J, NELSON H, GENT M: Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 1(8597):1242-1245.
21. SAOUR JN, SIECK JO, MAMO LAR, GALLUS AS: Trial of different intensities of anticoagulant therapy in patients with prosthetic heart valves. N. Engl. J. Med. (1990) 322(7):428-432. (Pubitemid 20059511)
22. FUSTER V, PUMPHREY CW, MCGOON MD, CHESEBRO JH, PLUTH JR, MCGOON DC: Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation (1982) 66(2 Pt 2):1157-1161.
23. PETERSEN P, BOYSEN G, GODTFREDSEN J, ANDERSEN ED, ANDERSEN B: Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet (1989) 1:175-179. (Pubitemid 19038801)
24. BOSTON AREA ANTICOAGULATION TRIAL FOR ATRIAL FIBRILLATION INVESTIGATORS: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. (1990) 323(22):1505-1511.
25. CONNOLLY SJ, LAUPACIS A, GENT M et al.: Canadian atrial fibrillation anticoagulation (CAFA) study. J. Am. Coll. Cardiol. (1991) 18:349-355.
26. EZEKOWITZ MD, BRIDGERS SL, JAMES KE et al.: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N. Engl. J. Med. (1992) 327:1406-1412.
27. LEVINE MN, RASKOB G, LANDEFELD CS: Hemorrhagic complications of anticoagulant treatment. Chest (1995) 108(Suppl. 4):276S-290S.
28. FIHN SD, MCDONELL M, MARTIN D et al.: Risk factors for complications of chronic anticoagulation. A multicenter study. Ann. Intern. Med. (1993) 118(7):511-520. (Pubitemid 23085793)
29. LANDEFELD CS, ANDERSON PA, GOODNOUGH LT et al.: The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J. Clin. Epidemiol. (1989) 42:711-718. (Pubitemid 19213115)
30. HULL R, HIRSH J, JAY R et al.: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N. Engl. J. Med. (1982) 307(27):1676-1681. (Pubitemid 13206049)
31. ALTMAN R, ROUVIER J, GURFINKEL E: Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J. Thorac. Cardiovasc. Surg. (1991) 101:427-431.
32. HYLEK EM, SINGER DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann. Intern. Med. (1994) 120:897-902. (Pubitemid 24179151)
33. CANNEGIETER SC, ROSENDAAL FR, WINTZEN AR, VAN DER MEER FJ, VANDENBROUCKE JP, BRIET E: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med. (1995) 333(1):11-17.
34. EUROPEAN ATRIAL FIBRILLATION TRIAL STUDY GROUP: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N. Engl. J. Med. (1995) 333:5-10.
35. LANDEFELD CS, GOLDMAN L: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. (1989) 87:144-152. (Pubitemid 19201634)
36. LANDEFELD CS, ROSENBLATT MW, GOLDMAN L: Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am. J. Med. (1989) 87:153-159. (Pubitemid 19201635)
37. ATRIAL FIBRILLATION INVESTIGATORS: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. (1994) 154:1449-1457
38. EAFT (EUROPEAN ATRIAL FIBRILLATION TRIAL) STUDY GROUP: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet (1993) 342:1255-1262.
39. HYLEK EM, SKATES SJ, SHEEHAN MA, SINGER DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. (1996) 335:540-546. (Pubitemid 26272308)
40. ANSELL JE: Anticoagulation management as a risk factor for adverse events: grounds for improvement. J. Thromb. Thrombolysis (1998) 5(Suppl.):S13-S18.
41. SAMSA GP, MATCHAR DB, GOLDSTEIN LB et al.: Quality of anticoagulation management among patients with atrial fibrillation. Results of a review of medical records from 2 communities. Arch. Intern. Med. (2000) 160:967-973. (Pubitemid 30191925)
42. ANSELL J: The quality of anticoagulant management. Arch. Intern. Med. (2000) 160:895-896.
43. ROSENDAAL FR, CANNEGIETER SC, VAN DER MEER FJM, BRIET E: A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. (1993) 69(3):236-239. (Pubitemid 23069000)
44. LANDEFELD CS, BEYTH RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am. J. Med. (1993) 95:315-328. (Pubitemid 23270290)
45. BEYTH RJ, QUINN LM, LANDEFELD CS: Prospective evaluation of an index for predicting risk of major bleeding in outpatients treated with warfarin. Am. J. Med. (1998) 105:91-99. (Pubitemid 28405230)
46. LEVINE MN, RASKOB G, LANDEFELD CS, KEARON C: Hemorrhagic complications of anticoagulant treatment. Chest (2001) 119(1 Suppl.):108S-121S. (Pubitemid 32154197)
47. LAUNBJERG J, EGEBLAD H, HEAF J, NIELSEN NH, FUGLEHOLM AM, LADEFOGED K: Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J. Intern. Med. (1991) 229:351-355.
48. KUIJER PMM, HUTTEN BA, PRINS MH, BULLER HR: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch. Intern. Med. (1999) 159:457-460. (Pubitemid 29108910)
49. BEYTH RJ, SHORR RI: Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging (1999) 14(3):231-239. (Pubitemid 29123601)
50. GURALNIK JM, LACROIX AZ, EVERETT DF, KOVAR MG: Aging in the eighties: the prevalence of comorbidity and association with disability. National Center for Health Statistics (ed.). Advance Data from Vital and Health Statistics, (PHS) 89-1250. (1989) 170:1-8. Hyattsville, USA. Department of Health and Human Services. 26 May 1989.
51. SEEMAN TE, GURALNIK J, KAPLAN GA, KNUDSEN L, COHEN R: The health consequences of multiple morbidity in the elderly. The Alameda County Study. J. Aging Health (1989) 1:50-66. (Pubitemid 20049827)
52. US SENATE SPECIAL COMMITTEE ON AGING (1987-88): Aging America, 1988: Trends and Projections. Washington DC: US Department of Health and Human Services, 1991.
53. HART RG, BOOP BS, ANDERSON DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke (1995) 26(8):1471-1477.
54. NOLAN L, O'MALLEY K: Prescribing for the elderly. Part II. Prescribing patterns: difference due to age. J. Am. Geriatr. Soc. (1988) 36:245-254. (Pubitemid 18078060)
55. TOOHEY M: Clinical trial of phenylindanedione as an anticoagulant. Br. Med. J. (1953) 1:650-662.
56. GURWITZ JH, AVORN J, ROSSDEGNAN D, CHOODNOVSKIY I, ANSELL J: Aging and the anticoagulant response to warfarin therapy. Ann. Intern. Med. (1992) 116:901-904. (Pubitemid 23034781)
57. O'MALLEY K, STEVENSON IH, WARD CA, WOOD AJJ, CROOKS J: Determinants of anticoagulant control in patients receiving warfarin. Br. J. Clin. Pharmacol. (1977) 4:309-314. (Pubitemid 8116771)
58. SHEPHERD AMM, HEWICK DS, MORELAND TA, STEVENSON IH: Age as a determinant of sensitivity to warfarin. Br. J. Clin. Pharmacol. (1977) 4:315-320. (Pubitemid 8116772)
59. FRIEDMAN SA: Organ systems: cardiovascular disorders. In: The Merck Manual of Geriatrics. Abrams WB, Berkow R (eds). Merck Sharp and Dohme Research Laboratories, Rahway, USA. (1990):408.
60. MASUDA J, TANAK K, UEDA K, OMAE T: Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke (1988) 19(2):205-210. (Pubitemid 18084394)
61. VONSATTEL JP, MYERS RH, HEDLEYWHYTE ET, ROPPER AH, BIRD ED, RICHARDSON EP JR: Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann. Neurol. (1991) 30(5):637-649.
62. COON WW, WILLIS PWI: Hemorrhagic complications of anticoagulant therapy. Arch. Intern. Med. (1974) 133:386-392.
63. FIHN SD, CALLAHAN CM, MARTIN DC, MCDONNELL MB, HENIKOFF JG, WHITE RH: The risk and severity of bleeding complications in elderly patients treated with warfarin. Ann. Intern. Med. (1996) 124:970-979.
64. PALARETI G, LEALI N, COCCHERI S et al.: Bleeding complications of oral anticoagulant treatment: an inceptioncohort, prospective collaborative study (ISCOAT). Lancet (1996) 348:423-428. (Pubitemid 26267872)
65. PETITTI DB, STROM BL, MELMON KL: Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J. Clin. Epidemiol. (1989) 42:759-764. (Pubitemid 19213122)
66. POLLARD JW, HAMILTON MJ, CHRISTENSEN NA, ACHOR RWP: Problems associated with long-term anticoagulant therapy. Circulation (1962) 25:311-317.
67. STROKE PREVENTION IN ATRIAL FIBRILLATION INVESTIGATORS: Stroke prevention in atrial fibrillation study. Final results. Circulation (1991) 84:527-539.
68. VAN DER MEER FJM, ROSENDAAL FR, VANDENBROUCKE JP, BRIET E: Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch. Intern. Med. (1993) 153:1557-1562. (Pubitemid 23205854)
69. DAVIS FB, ESTRUCH MT, SAMSONCORVERA EB, VOIGT GC, TOBIN JD: Management of anticoagulation in outpatients. Experience with an anticoagulation service in a municipal hospital setting. Arch. Intern. Med. (1977) 137:197-202. (Pubitemid 9033798)
70. FORFAR JC: A 7-year analysis of hemorrhage in patients on long-term anticoagulant treatment. Br. Heart J. (1979) 42:128-132. (Pubitemid 9241530)
71. GURWITZ JH, GOLDBERG RJ, HOLDEN A, KNAPIC N, ANSELL J: Agerelated risks of long-term oral anticoagulant therapy. Arch. Intern. Med. (1988) 148:1733-1736.
72. LUNDSTROM T, RYDEN L: Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J. Intern. Med. (1989) 225:137-142. (Pubitemid 19119720)
73. MCINNES GT, HELENGLASS G: The performance of clinics for outpatient control of anticoagulation. J. Royal Coll. Phys. London (1987) 21:42-45. (Pubitemid 17214539)
74. PEYMAN MA: The significance of hemorrhage during the treatment of patients with the coumarin anticoagulants. Acta Med. Scand. (1958) 339:1-62.
75. BEYTH RJ, LANDEFELD CS: Anticoagulants in older patients: a safety perspective. Drugs Aging (1995) 6:45-54.
76. BRECKENRIDGE AM: Interindividual differences in the response to oral anticoagulants. Drugs (1977) 14:367-375. (Pubitemid 8218331)
77. LOUSBERG TR, WITT DM, BEALL DG, CARTER BL, MALONE DC: Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch. Intern. Med. (1998) 158(5):528-534. (Pubitemid 128681614)
78. WHITE RH, MCKITTRICK T, HUTCHINSON R, TWITCHELL J: Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann. Intern. Med. (1995) 122(1):40-42.
79. 1. Thromb. Haemost. (1992) 67(1):13-15.
80. MARTIN D, AUSTIN H: An efficient program for computing conditional maximum likelihood estimates and exact confidence limits for a common odds ratio. Epidemiology (1991) 2:359-362.
81. WHITLING AM: Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch. Intern. Med. (1998) 158(19):2136-2140. (Pubitemid 28482097)
82. RAJ G, KUMAR R, MCKINNEY P: Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch. Intern. Med. (1999) 159:2721-274.
83. 1) compared with warfarin discontinuation. Blood Coagul. Fibrinolysis (1993) 4:739-741. (Pubitemid 23343397)
84. 1. Ann. Intern. Med. (1997) 125:959-962. (Pubitemid 27255799)
85. CROWTHER MA, DONOVAN D, HARRISON L, MCGINNIS J, GINSBERG J: Low dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb. Haemost. (1998) 79(6):1116-1118. (Pubitemid 28297157)
86. WHITE RH, MCKITTRICK T, TAKAKUWA J, CALLAHAN C, MCDONELL M, FIHN S: Management and prognosis of life-threatening bleeding during warfarin therapy. Arch. Intern. Med. (1996) 156:1197-1201. (Pubitemid 26196247)
87. MARKIS M, GREAVES M, PHILLIPS WS, KITCHEN S, ROSENDAAL FR, PRESTON EF: Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb. Haemost. (1997) 77(3):477-480. (Pubitemid 27121012)
88. JAFFIN BW, BLISS CM, LAMONT JT: Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am. J. Med. (1987) 83:269-272.
89. CULCLASURE TF, BRAY VJ, HASBARGEN JA: The significance of hematuria in the anticoagulated patient. Arch. Intern. Med. (1994) 154:649-652. (Pubitemid 24096194)
90. CARALIS P, GELBARD M, WASHER J, RHAMY R, MARCIAL E: Incidence and etiology of hematuria in patients on anticoagulant therapy. Clin. Res. (1989) 37:791A.
91. SCHUSTER GA, LEWIS GA: Clinical significance of hematuria in patients on anticoagulant therapy. J. Urol. (1987) 137:923-925. (Pubitemid 17074895)
92. VAN SAVAGE JG, FRIED FA: Anticoagulant associated hematuria: a prospective study. J. Urol. (1995) 153:1594-1596.